Mera Pharmaceuticals Stock Performance
| MRPI Stock | USD 0.0001 0.00 0.00% |
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Mera Pharmaceuticals are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Mera Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Mera Pharmaceuticals is not utilizing all of its potentials. The recent stock price confusion, may contribute to short-horizon losses for the traders. ...more
Mera |
Mera Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.01 in Mera Pharmaceuticals on November 17, 2025 and sell it today you would earn a total of 0.00 from holding Mera Pharmaceuticals or generate 0.0% return on investment over 90 days. Mera Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Mera, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mera Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Mera Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Mera Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Mera Pharmaceuticals generated a negative expected return over the last 90 days | |
| Mera Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Mera Pharmaceuticals currently holds 299.14 K in liabilities. Mera Pharmaceuticals has a current ratio of 0.06, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Mera Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Mera Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mera Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mera to invest in growth at high rates of return. When we think about Mera Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 302.62 K. Net Loss for the year was (5.58 K) with profit before overhead, payroll, taxes, and interest of 286.36 K. | |
| Mera Pharmaceuticals currently holds about 4.32 K in cash with (71.84 K) of positive cash flow from operations. |
Mera Pharmaceuticals Fundamentals Growth
Mera Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Mera Pharmaceuticals, and Mera Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mera Pink Sheet performance.
| Return On Asset | -1.74 | |||
| Current Valuation | 167.19 K | |||
| Shares Outstanding | 557.3 M | |||
| Price To Sales | 3.62 X | |||
| Revenue | 302.62 K | |||
| EBITDA | (192.75 K) | |||
| Cash And Equivalents | 4.32 K | |||
| Total Debt | 299.14 K | |||
| Cash Flow From Operations | (71.84 K) | |||
| Total Asset | 71 K | |||
| Retained Earnings | (8.89 M) | |||
| Current Asset | 54 K | |||
| Current Liabilities | 935 K |
About Mera Pharmaceuticals Performance
By evaluating Mera Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Mera Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Mera Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Mera Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Mera Pharmaceuticals, Inc. focuses on the development and commercialization of natural products from microalgae using its proprietary and large-scale photobioreactor technology. Mera Pharmaceuticals, Inc. was founded in 1983 and is based in Las Vegas, Nevada. Mera Pharma is traded on OTC Exchange in the United States.Things to note about Mera Pharmaceuticals performance evaluation
Checking the ongoing alerts about Mera Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Mera Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mera Pharmaceuticals generated a negative expected return over the last 90 days | |
| Mera Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Mera Pharmaceuticals currently holds 299.14 K in liabilities. Mera Pharmaceuticals has a current ratio of 0.06, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Mera Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Mera Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mera Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mera to invest in growth at high rates of return. When we think about Mera Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 302.62 K. Net Loss for the year was (5.58 K) with profit before overhead, payroll, taxes, and interest of 286.36 K. | |
| Mera Pharmaceuticals currently holds about 4.32 K in cash with (71.84 K) of positive cash flow from operations. |
- Analyzing Mera Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mera Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Mera Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mera Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mera Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mera Pharmaceuticals' pink sheet. These opinions can provide insight into Mera Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Mera Pink Sheet analysis
When running Mera Pharmaceuticals' price analysis, check to measure Mera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mera Pharmaceuticals is operating at the current time. Most of Mera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Mera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Mera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |